Published in Q J Med on February 01, 1986
Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). Br Med J (Clin Res Ed) (1987) 1.33
Paget's disease of bone. BMJ (1992) 1.04
Clinical efficacy of oral risedronate therapy in Japanese patients with Paget's disease of bone. J Bone Miner Metab (2014) 0.75
Nomogram for derivation of renal threshold phosphate concentration. Lancet (1975) 3.20
Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J (1980) 2.29
Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner (1986) 2.23
Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Lancet (1979) 2.02
Comparison of intravenous (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate and volume repletion in tumour-induced hypercalcaemia. Lancet (1983) 2.00
Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet (1987) 1.90
Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Lancet (1979) 1.78
Effects of calcitonin on patients with Paget's disease, thyrotoxicosis, or hypercalcaemia. Lancet (1968) 1.77
Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma. Cancer (1985) 1.74
Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) in rats. Calcif Tissue Int (1980) 1.65
Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis. Biochem Biophys Res Commun (1989) 1.64
Efficacious management with aminobisphosphonate (APD) in Paget's disease of bone. Clin Orthop Relat Res (1987) 1.55
The assessment of phosphate reabsorption. Clin Chim Acta (1969) 1.42
[Consensus conference on osteoporosis]. Ned Tijdschr Geneeskd (1986) 1.39
Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). Br Med J (Clin Res Ed) (1987) 1.33
Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol (1993) 1.32
Enhancement of the inhibitory action of APD on the transformation of osteoclast precursors into resorbing cells after dimethylation of the amino group. Bone Miner (1987) 1.31
Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate. J Bone Miner Res (1988) 1.22
Natriuretic effect of calcitonin in man. N Engl J Med (1971) 1.21
Stimulation of bone resorption by inflamed nasal mucosa, dermonecrotic toxin-containing conditioned medium from Pasteurella multocida, and purified dermonecrotic toxin from P. multocida. Infect Immun (1987) 1.19
APD in Paget's disease of bone. Role of the mononuclear phagocyte system? Arthritis Rheum (1980) 1.18
Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. Bone Miner (1989) 1.15
Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride. Am J Med (1987) 1.13
Characteristics and bisphosphonate treatment of a patient with juvenile osteoporosis. J Clin Endocrinol Metab (1985) 1.12
Crystal agglomeration is a major element in calcium oxalate urinary stone formation. Kidney Int (1990) 1.06
Paget's bone disease treated with diphosphonate and calcitonin. Lancet (1976) 1.05
Relation of plasma phosphate concentration to renal tubular reabsorption of phosphate. Clin Sci (1969) 1.02
Excessive crystal agglomeration with low citrate excretion in recurrent stone-formers. Lancet (1986) 1.00
Bone scintigraphy and radiology in Paget's disease of bone: a review. Am J Physiol Imaging (1988) 0.99
Differential action of the bisphosphonates (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (Cl2MDP) on rat macrophage-mediated bone resorption in vitro. J Clin Invest (1982) 0.98
Effects of decreasing serum calcium on circulating parathyroid hormone and vitamin D metabolites in normocalcaemic and hypercalcaemic patients treated with APD. Bone Miner (1986) 0.94
Regression of bone lesions in Gaucher's disease during treatment with aminohydroxypropylidene bisphosphonate. Lancet (1984) 0.93
A simple slide-rule method for the assessment of renal tubular reaborption of phosphate in man. Clin Chim Acta (1977) 0.93
Clinical and biological effects of low doses of (3 amino-1 hydroxypropylidene)-1,1-bisphosphonate (APD) in Paget's disease of bone. Eur J Clin Invest (1982) 0.92
Renal phosphate excretion in man. Folia Med Neerl (1972) 0.92
Serum osteocalcin in Paget's disease of bone: basal concentrations and response to bisphosphonate treatment. J Clin Endocrinol Metab (1987) 0.91
Familial benign hypercalcaemia. Study of a large family. Q J Med (1983) 0.91
Primary oxalosis: clinical and biochemical response to high-dose pyridoxine therapy. Metabolism (1979) 0.91
Effect of a diphosphonate on para-articular ossification after total hip replacement. Acta Orthop Scand (1974) 0.90
The use of bisphosphonates in the treatment of osteoporosis. Bone (1992) 0.89
Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate. J Clin Oncol (1986) 0.88
Results of prolonged treatment of Paget's disease of bone with disodium ethane-1-hydroxy-1, 1-diphosphonate (EHDP). Neth J Med (1974) 0.88
Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium. Calcif Tissue Int (1982) 0.87
Osteolytic bone metastases in breast carcinoma pathogenesis, morbidity and bisphosphonate treatment. Eur J Cancer Clin Oncol (1986) 0.87
Modulation of calcium oxalate monohydrate crystallization kinetics in vitro. Kidney Int (1988) 0.87
Radiological demonstration of healing in Paget's disease of bone treated with APD. Br J Radiol (1985) 0.86
Ectopic production of 1,25-dihydroxyvitamin D by B-cell lymphoma as a cause of hypercalcemia. Cancer (1987) 0.86
Untreated Paget disease of bone studied by scintigraphy. Radiology (1984) 0.85
Inorganic pyrophosphatase in mineralizing hamster molars. 3. Influence of diphosphonates. Calcif Tissue Res (1973) 0.84
Severe influenza resembling hemorrhagic shock and encephalopathy syndrome. J Clin Virol (2007) 0.84
Relationship of inorganic pyrophosphatase and alkaline phosphatase activities in hamster molars. Calcif Tissue Res (1970) 0.84
Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate. J Bone Miner Res (1989) 0.84
In vitro effect of (3-amino-1-hydroxypropylidene)-1,1-bisphosphonic acid (APD) on the function of mononuclear phagocytes in lymphocyte proliferation. Immunology (1982) 0.83
The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. Eur J Cancer (1991) 0.82
Modulation of the production of a parathyroid hormone-like protein in human squamous carcinoma cell lines by interaction with fibroblasts. Cancer Res (1990) 0.82
Apparent mineralocorticoid excess and deficient 11 beta-oxidation of cortisol in a young female. Clin Endocrinol (Oxf) (1984) 0.82
Modulation of PTH-stimulated osteoclastic resorption by bisphosphonates in fetal mouse bone explants. J Bone Miner Res (1991) 0.81
Apposition and resorption of bone during oral treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Calcif Tissue Int (1983) 0.81
Polysaccharide from coccoliths (CaCO3 biomineral). Influence on crystallization of calcium oxalate monohydrate. Eur J Biochem (1986) 0.80
Effects of long-term porcine calcitonin administration in patients with Paget's disease or osteoporosis. Calcif Tissue Res (1970) 0.80
Combined diphosphonate and calcitonin therapy for Paget's disease of bone. Calcif Tissue Res (1976) 0.80
Familial benign hypercalcaemia (FBH; McK. No. 14598, 1983): linkage studies in a large Dutch family. Hum Genet (1984) 0.79
Iliac bone marrow trephine biopsy: some remarks on the technique. Neth J Med (1978) 0.79
Low inhibition of crystal agglomeration and citrate excretion in recurrent calcium oxalate stone formers. Contrib Nephrol (1987) 0.79
Bone scintigraphy in Paget's disease treated with combined calcitonin and diphosphonate (EHDP). Metab Bone Dis Relat Res (1982) 0.78
Formation of antibodies to synthetic human calcitonin during treatment of Paget's disease. Acta Endocrinol (Copenh) (1979) 0.78
Plasma-phosphate and tubular reabsorption of phosphate. Lancet (1970) 0.78
Limited precision of lumbar spine dual-photon absorptiometry by variations in the soft-tissue background. J Nucl Med (1990) 0.77
Magnetic resonance imaging in Paget disease of the skull. AJNR Am J Neuroradiol (1986) 0.77
The eosinophilic fibrohistiocytic lesion of the bone marrow. A mastocellular lesion in bone disease. Virchows Arch A Pathol Anat Histol (1978) 0.77
Regulation of the production of plasminogen activators by bone resorption enhancing and inhibiting factors in three types of osteoblast-like cells. Bone Miner (1991) 0.76
Regulation of calcium absorption by 1,25,dihydroxy-vitamin D--studies of the effects of a bisphosphonate treatment. Calcif Tissue Int (1982) 0.76
Kidney-mediated effects of parathyroid hormone on extracellular homoeostasis of calcium, phosphate and acid-base balance in man. Neth J Med (1974) 0.75
Calcitonin or EHDP in Paget's disease? Calcif Tissue Res (1977) 0.75
Scintigraphic aspects of the recurrence of treated Paget's disease of bone. J Nucl Med (1981) 0.75
The Zollinger-Ellison syndrome. Observations on eight patients. Neth J Med (1974) 0.75
Bisphosphonates can reduce osteoclastic bone resorption by two different mechanisms. Adv Exp Med Biol (1986) 0.75
[Milk-alkali syndrome]. Ned Tijdschr Geneeskd (1986) 0.75
A tumour-like bone lesion as a manifestation of vitamin D-resistant hypophosphataemic osteomalacia. Br J Radiol (1987) 0.75
The reproducibility of single photon absorptiometry in a clinical setting. Eur J Nucl Med (1989) 0.75
Effect of long-term bisphosphonate treatment on morbidity due to bone metastases in breast cancer patients. Recent Results Cancer Res (1989) 0.75